

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICATION OF:

Lim, et al.

APPLICATION No.: 09/518,297

FILED: March 3, 2000

FOR: DNA BINDING COMPOUND-MEDIATED

MOLECULAR SWITCH SYSTEM

EXAMINER: Kam, Chih-Min

ART UNIT: 1653

CONF. No: 5390

Declaration Under 37 C.F.R. § 1.821

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

- I, Norbert Stahl, declare and affirm as follows:
- 1. I am an agent for the applicant.
- 2. The diskette which accompanies this Declaration contains the required sequence listing.
- 3. The sequence listing recorded on said diskette is identical to the hard copy of the sequence listing accompanying this Declaration.
- 4. The present submission contains no new matter relative to the application as originally filed.

Date.

Ī

Deul

Perking Coie LLP

Norbert Stahl

Registration No. 44,350

Respectfully submitted,

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300



Notice to Comply

Application No. 09/518,297	Applicant(s) Lim et al.	
Examiner	Art Unit	
C.M. Kam	1653	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

the	requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
\boxtimes	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
\boxtimes	7. Other: nucleotide sequences cited in the specification (e.g., Tables 9 and 10), however, the sequence identifier "SEQ ID NO:" is not indicated in the sequence listing.
Ар	plicant Must Provide:
\boxtimes	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
⊠ into	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.
	A statement that the content of the paper and computer readable copies are the same and, where

applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

Patentin Software Program Support

1.825(d).

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY